analyst
NASDAQ · BMRN
BioMarin Pharmaceutical Inc.
Healthcare · Biotechnology
$64.45
Down-$1.96 (-2.95%)
Updated Sep 16, 2026, 8:43 AM
SID Score
6.5/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 10.18B
- P/E ratio
- 19.56
- Dividend yield
- 0.00%
- 52-week range
- $49.26 – $70.98
- Volume
- 1.85M
- Avg. volume
- 2.67M
Price performance
BMRN price history
1M range · 20 trading sessions · Daily adjusted prices
BMRN closed at $64.45 after 20 trading sessions, down 3.79% for the selected period.
- Last close
- $64.45
- Period change
- -3.79%
- Period low
- $64.41
- Period high
- $69.33
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $65.78 | $65.78 | $63.85 | $64.45 | 1.85M |
| Sep 14, 2026 | $66.27 | $66.88 | $65.72 | $66.41 | 1.34M |
| Sep 11, 2026 | $65.96 | $66.05 | $65.285 | $65.68 | 1.6M |
| Sep 10, 2026 | $64.41 | $65.59 | $63.5742 | $65.51 | 2.2M |
| Sep 9, 2026 | $63.83 | $65.325 | $63.64 | $64.41 | 1.95M |
| Sep 8, 2026 | $65.24 | $66.26 | $64.01 | $64.63 | 1.46M |
| Sep 4, 2026 | $65.785 | $66.64 | $65.52 | $66.53 | 2.3M |
| Sep 3, 2026 | $67.30 | $67.695 | $66.32 | $66.43 | 1.48M |
| Sep 2, 2026 | $65.00 | $67.20 | $64.99 | $66.97 | 2.52M |
| Sep 1, 2026 | $65.54 | $66.015 | $64.49 | $64.84 | 1.78M |
| Aug 31, 2026 | $65.95 | $66.2972 | $64.33 | $65.23 | 2.3M |
| Aug 28, 2026 | $64.99 | $65.08 | $64.07 | $64.665 | 1.1M |
| Aug 27, 2026 | $65.28 | $65.915 | $64.83 | $65.29 | 1.25M |
| Aug 26, 2026 | $65.62 | $66.5322 | $65.33 | $65.61 | 1.88M |
| Aug 25, 2026 | $65.03 | $66.36 | $65.02 | $66.12 | 1.36M |
| Aug 24, 2026 | $66.57 | $67.18 | $64.71 | $65.07 | 2.26M |
| Aug 21, 2026 | $67.55 | $68.34 | $66.52 | $66.70 | 1.59M |
| Aug 20, 2026 | $68.106 | $68.75 | $67.565 | $67.68 | 1.28M |
| Aug 19, 2026 | $68.17 | $69.62 | $67.75 | $69.33 | 1.98M |
| Aug 18, 2026 | $67.21 | $68.265 | $66.84 | $66.99 | 1.94M |
Latest BMRN news
The latest Smart Investors Daily articles mentioning BMRN.
Stock researchCompany · Overview
BMRN research
Overview
Company profile and research snapshot.
Company profile
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $80.58
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HC Wainwright & Co. | Neutral | — |
| Sep 1, 2026 | Piper Sandler | Overweight | — |
| Aug 31, 2026 | HC Wainwright & Co. | Neutral | — |
| Aug 31, 2026 | Jefferies | Buy | — |
| Aug 19, 2026 | BMO Capital | Outperform | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.